Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

Journal of Gastroenterology

Volumn 47, Issue 2, 2012, Pages 179-186

  Imai, Yukinori ^a   Chikayama, Taku ^a   Nakazawa, Manabu ^a   Watanabe, Kazuhiro ^a   Ando, Satsuki ^a   Mizuno, Yoshie ^a   Yoshino, Kiyoko ^a   Sugawara, Kayoko ^a   Hamaoka, Kazuhiro ^a   Fujimori, Kenji ^a   Inao, Mie ^a   Nakayama, Nobuaki ^a   Oka, Masashi ^a   Nagoshi, Sumiko ^a   Mochida, Satoshi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Lipiodol; Miriplatin; Transcatheter arterial chemoembolization

Indexed keywords

MIRIPLATIN; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER STAGING; CHEMOEMBOLIZATION; CREATININE BLOOD LEVEL; DRUG FEVER; FEMALE; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SAFETY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; HEPATIC ARTERY; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; FEMALE; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84863094892     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0475-x     Document Type: Article

References (25)

1. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl):102-7.
2. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, et al. Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-85.
3. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res. 2005;32:163-72. (Pubitemid 41070387)
4. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200-7. (Pubitemid 36169630)
5. Rossi S, Buscarini E, Garbagnati F, Garbagnati F, Stasi MD, Quaretti P, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. Am J Roentgenol. 1998;170:1015-22. (Pubitemid 28172891)
6. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small- sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224-9.
7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9. (Pubitemid 26079803)
8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9. (Pubitemid 34607087)
9. Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am J Radiology. 2003;181:1327-34. (Pubitemid 37296411)
10. Okusaka T, Kasugai H, Ishii H, SM-11355 Japan Study Group. A randomized phase II trial of intraarterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. J Clin Oncol. 2009;27:222s.
11. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987;163:345-51. (Pubitemid 17068905)
12. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. Am J Radiol. 2010;194:830-7.
13. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Tokyo: Kanehara; 2003.
14. Kudo M, Cung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol. 2003;38:207-15. (Pubitemid 36527122)
15. National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0. 2011. http://evs.nci.nih.gov/ftp1/CTCAE/. Accessed 9 May 2011.
16. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology. 1985;154:15-7. (Pubitemid 15196276)
17. Taguchi T, Saito T, Ota J, Nakao I, Ohashi K, Nakamura H, et al. Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Jpn J Cancer Chemother. 1991;18:1665-75.
18. Maeda H, Uchida NA, Sasaki T. Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res. 1986;77:523-5. (Pubitemid 16061614)
19. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y. In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol. Biol Pharm Bull. 2000;23:637-40. (Pubitemid 30321287)
20. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by including platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-83.
21. Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology. 2004;66:24-31. (Pubitemid 38410676)
22. Ono Y, Yoshimaru T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000;23:564-8. (Pubitemid 32429101)
23. Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anti-Cancer Drugs. 2011;22:277-82.
24. Kawamura Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, et al. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemo-embolization with epirubicin. Hepatol Res. 2009;39:346-54.
25. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474-83. (Pubitemid 351593948)